Search

Your search keyword '"Nicoletta Botto"' showing total 2 results
Start Over Author "Nicoletta Botto" Publisher walter de gruyter gmbh
2 results on '"Nicoletta Botto"'

1. Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening testing / Faktor-V-Leiden, Prothrombin G20210A Substitution und Hormontherapie: Indikationen für molekulare Screening Tests

Author

Nicoletta Botto, Silvia Maffei, and Maria Grazia Andreassi

Subjects
Thrombotic risk, Gynecology, medicine.medical_specialty, Molecular screening, Screening test, business.industry, medicine.medical_treatment, Biochemistry (medical), Clinical Biochemistry, Hormonal replacement therapy, medicine.disease, Medical Laboratory Technology, medicine, Factor V Leiden, Prothrombin G20210A, Hormone therapy, Inherited thrombophilia, business
Published
2006
Full Text
View/download PDF

2. Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening

Author

Silvia Maffei, Nicoletta Botto, and Maria Grazia Andreassi

Subjects
Risk, medicine.medical_specialty, Hormone Replacement Therapy, medicine.medical_treatment, Clinical Biochemistry, Bioinformatics, Thrombophilia, Internal medicine, medicine, Factor V Leiden, Animals, Humans, Mass Screening, Hormone metabolism, Hormone replacement therapy, Risk factor, Genetic testing, Polymorphism, Genetic, medicine.diagnostic_test, business.industry, Biochemistry (medical), Factor V, Estrogens, Thrombosis, General Medicine, medicine.disease, Hormones, Endocrinology, Mutation, Prothrombin G20210A, Female, Prothrombin, Hormone therapy, business, Contraceptives, Oral
Abstract

Venous thromboembolism is a well-known complication of oral contraception and hormonal replacement therapy. Inherited thrombophilia is viewed as an important determinant in modulating the effects of estrogens on thrombotic risk. An increasing number of kits for thrombophilic mutations [factor V Leiden, G20210A prothrombin and methylenetetrahydrofolate reductase (MTHFR) C677T genes] are becoming commercially available, and screening for inherited thrombotic risk is among the most requested genetic tests in molecular diagnostic laboratories. However, the question of routine genetic screening for thrombophilia before prescribing hormones is still a matter of debate. The purpose of this article is to discuss the usefulness and practical applications of thrombotic genetic testing to identify which women should be tested to improve both the safety and efficacy of individualized estrogen therapy.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results